


Bupivacaine

Cat. No.:	HY-B0405	
CAS No.:	38396-39-3	
Molecular Formula:	C ₁₈ H ₂₈ N ₂ O	
Molecular Weight:	288.43	
Target:	iGluR; Sodium Channel; Calcium Channel; Potassium Channel	
Pathway:	Membrane Transporter/Ion Channel; Neuronal Signaling	
Storage:	Powder	-20°C 3 years 4°C 2 years
	In solvent	-80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (346.70 mM; Need ultrasonic)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	3.4670 mL	17.3352 mL	34.6705 mL
	5 mM	0.6934 mL	3.4670 mL	6.9341 mL
	10 mM	0.3467 mL	1.7335 mL	3.4670 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Bupivacaine is a NMDA receptor inhibitor. Bupivacaine can block sodium, L-calcium, and potassium channels. Bupivacaine potentially blocks SCN5A channels with the IC₅₀ of 69.5 μM. Bupivacaine can be used for the research of chronic pain^{[1][2][3]}.

IC₅₀ & Target

NMDA Receptor

In Vitro

Bupivacaine inhibits NMDA receptor-mediated synaptic transmission in the dorsal horn of the spinal cord, an area critically involved in central sensitization^[1].
 Bupivacaine influences the voltage dependency of channel activation and steady-state inactivation by shifting the membrane potential of half-maximal activation/inactivation toward somewhat more negative membrane potentials. In their inactivated state, SCN5A channels are slightly sensitive toward Bupivacaine IC₅₀=2.18±0.16 μM^[2].
 Bupivacaine reversibly inhibits the SK2 channel in a dose-dependent manner with the IC₅₀ of 16.5 μM^[3].
 MCE has not independently confirmed the accuracy of these methods. They are for reference only.
 Cell Viability Assay^[3]

Cell Line:	HEK 293 cells transfected with the SK2 gene (transfected cells were named SK2 cells)
Concentration:	10, 100, 1000 μ M
Incubation Time:	
Result:	The IC ₅₀ value was 16.5 μ M.

CUSTOMER VALIDATION

- Nat Commun. 2023 Jun 3;14(1):3224.
- Stem Cell Res Ther. 2021 Feb 4;12(1):107.
- Sci Rep. 2022 Jan 26;12(1):1378.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Meaghan A Paganelli, et al. Actions of Bupivacaine, a widely used local anesthetic, on NMDA receptor responses. J Neurosci. 2015 Jan 14;35(2):831-42.
- [2]. Alexander P Schwoerer, et al. A Comparative Analysis of Bupivacaine and Ropivacaine Effects on Human Cardiac SCN5A Channels. Anesth Analg. 2015 Jun;120(6):1226-34.
- [3]. Carsten Stoetzer, et al. Inhibition of Voltage-Gated Na⁺ Channels by Bupivacaine Is Enhanced by the Adjuvants Buprenorphine, Ketamine, and Clonidine. Reg Anesth Pain Med. Jul/Aug 2017;42(4):462-468.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA